Cytosorbents Crp Net Income Over Time
| CTSO Stock | USD 0.71 0.02 2.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cytosorbents Crp Performance and Cytosorbents Crp Correlation. Cytosorbents | Build AI portfolio with Cytosorbents Stock |
Will Health Care Equipment & Supplies sector continue expanding? Could Cytosorbents diversify its offerings? Factors like these will boost the valuation of Cytosorbents Crp. Projected growth potential of Cytosorbents fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cytosorbents Crp data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.18) | Revenue Per Share | Quarterly Revenue Growth 0.101 | Return On Assets | Return On Equity |
Investors evaluate Cytosorbents Crp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytosorbents Crp's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cytosorbents Crp's market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytosorbents Crp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytosorbents Crp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytosorbents Crp's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Cytosorbents Crp and related stocks such as Icecure Medical, Tela Bio, and Spectral AI Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICCM | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.7 M) | (3.8 M) | (3.3 M) | (2.9 M) | (3.5 M) | (4.8 M) | (4.8 M) | (10.1 M) | (17.2 M) | (14.7 M) | (15.3 M) | (13.8 M) | (13.1 M) |
| TELA | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.1 M) | (22.4 M) | (28.8 M) | (33.3 M) | (44.3 M) | (46.7 M) | (37.8 M) | (34.1 M) | (35.8 M) |
| MDAI | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (2.9 M) | (20.9 M) | (15.3 M) | (13.8 M) | (14.5 M) |
| SRTS | 107.6 K | 107.6 K | 107.6 K | 107.6 K | (3.7 M) | (237.3 K) | (346.4 K) | (3.7 M) | (2 M) | (1.7 M) | (6.8 M) | 4.1 M | 24.2 M | 485 K | 6.6 M | (7.7 M) | (7.3 M) |
| NMTC | (6 K) | (14 K) | (14 K) | (30.6 K) | (36.2 K) | (62.9 K) | (47.8 K) | (6.8 M) | (6.8 M) | (13.6 M) | (9.9 M) | (10 M) | (11.9 M) | (12.3 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| BDMD | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | 7.1 M | 11.7 M | 12.6 M | 10.5 M | 12.5 M | 14.3 M | 8.6 M |
| ECOR | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (35.8 M) | (55.8 M) | (45.1 M) | (23.5 M) | (17.2 M) | (22.2 M) | (18.8 M) | (11.9 M) | (13.7 M) | (14.4 M) |
| TELO | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (854.1 K) | (13.1 M) | (16.5 M) | (16.5 M) | (14.9 M) | (14.1 M) |
| BDSX | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (30.7 M) | (31.4 M) | (43.2 M) | (65.4 M) | (52.1 M) | (42.9 M) | (38.6 M) | (40.6 M) |
| SER | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (6.6 M) | (7.5 M) | (12.2 M) | (10.9 M) | (1.3 M) | (2.7 M) | 5.3 M | (11.1 M) | (12.8 M) | (13.5 M) |
Cytosorbents Crp and related stocks such as Icecure Medical, Tela Bio, and Spectral AI Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cytosorbents Crp financial statement analysis. It represents the amount of money remaining after all of Cytosorbents Crp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cytosorbents Crp | CTSO |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 305 College Road |
| Exchange | NASDAQ Exchange |
USD 0.71
Check out Cytosorbents Crp Performance and Cytosorbents Crp Correlation. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Cytosorbents Crp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.